Skip to content
DraconiticResearch
Search Sources API
186,125 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY-NC-NDCirculation Journal

Prognostic Impact of Quantitative Flow Ratio-Derived Physiology for Intermediate Non-Infarct-Related Artery in Acute Myocardial Infarction

Abstract

BACKGROUND: The optimal treatment for functionally insignificant intermediate stenosis in non-infarct-related artery (IRA) after acute myocardial infarction (AMI) remains controversial. We identified high-risk non-IRAs using quantitative flow ratio (QFR)-derived physiological indices and evaluated their prognostic and therapeutic implications. METHODS AND RESULTS: We retrospectively assessed QFR-derived physiology in 240 non-IRAs (189 deferred [Defer group], 51 treated [percutaneous coronary intervention (PCI) group]) with diameter stenosis ≥40% and QFR ≥0.8 in 205 AMI patients treated between January 2014 and December 2023. In the Defer group, physiological indices associated with target vessel failure (TVF) were identified, and their discriminative performance and optimal cut-off values were determined using time-dependent receiver operating characteristic curve analysis with the Youden index. Adding QFR pressure pullback gradient (PPG) to QFR significantly enhanced time-dependent risk reclassification, as reflected by net reclassification improvement (P=0.039) and integrated discrimination improvement (P=0.023). After stratification using Youden-derived 3-year optimal cut-off values of 0.88 for QFR and 0.78 for QFR-PPG, deferred non-IRAs with high-risk physiology (QFR <0.88 and QFR-PPG <0.78) had a significantly higher 3-year TVF rate than those without high-risk physiology (42.1% vs. 9.9%; P<0.001). Among high-risk non-IRAs, the TVF rate was significantly higher in the Defer than PCI group, whereas it was similar among non-IRAs without high-risk physiology (P for interaction=0.040). CONCLUSIONS: QFR-derived physiology, including QFR and QFR-PPG, can stratify high-risk non-IRAs and guide optimal treatment in patients with AMI.

Related

  1. Real‐Life Psychological Experiences and Cardiac Autonomic Physiology Among Survivors of a Myocardial Infarction in Midlife
    Viola Vaccarino, Hua She, Lisa Elon +13
    Journal of the American Heart AssociationPeer-reviewedCC BY-NC-ND2 citedCardiovascular medicineCrossref
  2. Dynamic Changes and Prognostic Impact of Ischemic Mitral Regurgitation in Recurrent Myocardial Infarction
    Chiharu Nishino, Shun Nishino, Akihiro Hayashida +7
    Circulation JournalPeer-reviewedCC BY-NC-NDFull text1 citedCardiovascular medicineJ-STAGE
  3. Prognostic Value of Serum Lipoprotein(a) Levels in Japanese Patients With ST-Segment Elevation Myocardial Infarction
    Keiko Nishiyama, Kensaku Nishihira, Michikazu Nakai +11
    Circulation JournalPeer-reviewedCC BY-NC-NDFull text2 citedSurgery & anaesthesiaJ-STAGE
  4. XGBoost Model With CMR Features for Prognostic Assessment in Patients With ST-Segment Elevation Myocardial Infarction
    Yizhi Zhang, Jiyuan Chen, Zhiguo Zou +8
    JACC AsiaPeer-reviewedCC BY-NC-ND 4.0Full text1 citedMedical imaging & radiologyPMC
  5. Clinical characteristics and in-hospital prognostic factors in young patients with myocardial infarction.
    Lin Jinxuan, Liao Yongfang, Liu Tingrong +1
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMCCrossref
BibTeX
@article{nakao2026prognostic,
  title = {{Prognostic Impact of Quantitative Flow Ratio-Derived Physiology for Intermediate Non-Infarct-Related Artery in Acute Myocardial Infarction}},
  author = {Sho Nakao and Takayuki Ishihara and Takuya Tsujimura and Yosuke Hata and Masaya Kusuda and Wataru Ariyasu and Subaru Fujii and Toshiaki Mano},
  journal = {Circulation Journal},
  year = {2026},
  month = jul,
  doi = {10.1253/circj.cj-25-1136},
  url = {https://www.jstage.jst.go.jp/article/circj/90/8/90_CJ-25-1136/_article},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Prognostic Impact of Quantitative Flow Ratio-Derived Physiology for Intermediate Non-Infarct-Related Artery in Acute Myocardial Infarction
AU  - Sho Nakao
AU  - Takayuki Ishihara
AU  - Takuya Tsujimura
AU  - Yosuke Hata
AU  - Masaya Kusuda
AU  - Wataru Ariyasu
AU  - Subaru Fujii
AU  - Toshiaki Mano
PY  - 2026
DA  - 2026/07/24
JO  - Circulation Journal
DO  - 10.1253/circj.cj-25-1136
UR  - https://www.jstage.jst.go.jp/article/circj/90/8/90_CJ-25-1136/_article
AB  - BACKGROUND: The optimal treatment for functionally insignificant intermediate stenosis in non-infarct-related artery (IRA) after acute myocardial infarction (AMI) remains controversial. We identified high-risk non-IRAs using quantitative flow ratio (QFR)-derived physiological indices and evaluated their prognostic and therapeutic implications. METHODS AND RESULTS: We retrospectively assessed QFR-derived physiology in 240 non-IRAs (189 deferred [Defer group], 51 treated [percutaneous coronary intervention (PCI) group]) with diameter stenosis ≥40% and QFR ≥0.8 in 205 AMI patients treated between January 2014 and December 2023. In the Defer group, physiological indices associated with target vessel failure (TVF) were identified, and their discriminative performance and optimal cut-off values were determined using time-dependent receiver operating characteristic curve analysis with the Youden index. Adding QFR pressure pullback gradient (PPG) to QFR significantly enhanced time-dependent risk reclassification, as reflected by net reclassification improvement (P=0.039) and integrated discrimination improvement (P=0.023). After stratification using Youden-derived 3-year optimal cut-off values of 0.88 for QFR and 0.78 for QFR-PPG, deferred non-IRAs with high-risk physiology (QFR <0.88 and QFR-PPG <0.78) had a significantly higher 3-year TVF rate than those without high-risk physiology (42.1% vs. 9.9%; P<0.001). Among high-risk non-IRAs, the TVF rate was significantly higher in the Defer than PCI group, whereas it was similar among non-IRAs without high-risk physiology (P for interaction=0.040). CONCLUSIONS: QFR-derived physiology, including QFR and QFR-PPG, can stratify high-risk non-IRAs and guide optimal treatment in patients with AMI.
SN  - 1347-4820
SN  - 1346-9843
ER  -